Energy balance
Orlistat (120 mg three times daily with meals) produces significant weight loss and improves coronary heart disease risk profiles in obese patients, primarily by reducing dietary fat absorption.
Take 120 mg of Orlistat with each main meal containing fat. This blocks about 30% of dietary fat absorption. Stick to a low-fat diet to minimize gastrointestinal side effects like oily spotting. This leads to greater weight loss and improved heart disease risk factors compared to diet and placebo alone.
Orlistat (Xenical, 120 mg three times daily with meals) is a novel, nonsystemic, nonsynergistic antiobesity agent that inhibits the absorption of dietary fat by about 30% [20]. In randomized, double-blind placebo controlled trials, weight loss can be achieved with dietary fat restriction [11-13].
Why this rating
The study is a randomized, double-blind, placebo-controlled trial, which is high-quality evidence, though the sample size is moderate (n=380).
Source
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study
Folke Lindgärde · Journal of Internal Medicine · 2000
DOI 10.1046/j.1365-2796.2000.00720.x
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →